Clinical Trial

A Study of DXC008 in Patients With Prostate Cancer and Other Solid Tumors

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a phase I, open-label, first-in-human clinical study designed to evaluate the safety, tolerability, MTD, DLT, RP2D, the PK characteristics, preliminary anti-tumor activity, the immunogenicity of DXC008 in patients with prostate cancer and other solid tumors such as Ewing sarcoma.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2025-04-11; most recent amendment 2026-07-03.
Status change: Not Yet Recruiting → Recruiting 2025-09-09
Trial Details
NCT Number NCT06926283
Lead Sponsor Hangzhou DAC Biotechnology Co., Ltd.
Conditions Prostate Cancer, Other Solid Tumors, Ewing Sarcoma
Enrollment 110 participants
Start Date 2025-05-15
Primary Completion 2030-04 (estimated)
Study Completion 2030-04 (estimated)
Updated on ClinicalTrials.gov 2026-07-07